The emerging roles of non-coding competing endogenous RNA in hepatocellular carcinoma

Gang Xu†, Wei-Yu Xu‡, Yao Xiao†, Bao Jin†, Shun-Da Du†*, Yi-lei Mao† and Zhong-Tao Zhang‡*

Abstract
Accumulating evidence has emerged revealing that noncoding RNAs (ncRNAs) play essential roles in the occurrence and development of hepatocellular carcinoma (HCC). However, the complicated regulatory interactions among various ncRNAs in the development of HCC are not entirely understood. The newly discovered mechanism of competing endogenous RNAs (ceRNAs) uncovered regulatory interactions among different varieties of RNAs. In recent years, a growing number of studies have suggested that ncRNAs, including long ncRNAs, circular RNAs and pseudogenes, play major roles in the biological functions of the ceRNA network in HCC. These ncRNAs can share microRNA response elements to affect microRNA affinity with target RNAs, thus regulating gene expression at the transcriptional level and both physiological and pathological processes. The ncRNAs that function as ceRNAs are involved in diverse biological processes in HCC cells, such as tumor cell proliferation, epithelial-mesenchymal transition, invasion, metastasis and chemoresistance. Based on these findings, ncRNAs that act as ceRNAs may be promising candidates for clinical diagnosis and treatments. In this review, we discuss the mechanisms and research methods of ceRNA networks. We also reviewed the recent advances in studying the roles of ncRNAs as ceRNAs in HCC and highlight possible directions and possibilities of ceRNAs as diagnostic biomarkers or therapeutic targets. Finally, the limitations, gaps in knowledge and opportunities for future research are also discussed.

Keywords: Hepatocellular carcinoma, Noncoding RNA, Competing endogenous RNA

Background
Hepatocellular carcinoma (HCC), the most prevalent subtype of hepatic malignancy, is one of the leading causes of cancer-associated mortality worldwide [1]. There are an estimated 62 million new cases of HCC annually, 85% of which are diagnosed in developing countries [2]. Owing to the insidious symptoms and early metastases, most HCC patients are diagnosed at an advanced stage, leading to limited efficacy and even ineffectiveness of therapeutic approaches [3]. Despite continuous therapeutic advances, such as in surgical resection, liver transplantation and radiofrequency ablation, the 5-year survival rate for HCC patients is still under 20% [4, 5]. Therefore, it is important to identify the underlying mechanism as well as precise diagnostic and prognostic biomarkers for early diagnosis and risk assessment. Furthermore, identifying effective therapeutic targets for HCC is critical.

Carcinogenesis is a complicated multi-step, multi-stage process involving both genetic and epigenetic alterations [3]. However, the molecular pathogenesis of HCC remains unclear. Furthermore, the majority of previous
studies that examined the molecular mechanisms of hepatic tumorigenesis have focused on protein-coding genes and not yet provided comprehensive and detailed mechanisms of HCC. High-throughput sequencing technology has revealed numerous large and small non-coding RNAs (ncRNAs) that are critically involved in carcinogenesis [6]. NcRNAs, which universally exist in a broad range of organisms, are a group of RNAs without protein-coding functions and include long non-coding RNA (lncRNA), microRNA (miRNA), pseudogene, circular RNA (circRNA), small interfering RNA, small nucleolar RNA, ribosomal RNA and transfer RNA (Fig. 1). LncRNA, miRNA, pseudogene and circRNA are primarily involved in post-transcriptional regulation [7]. Recently, accumulating evidence has demonstrated that these ncRNAs are potential diagnostic and prognostic biomarkers for HCC [8–10]. Nevertheless, the specific functions and mechanisms of most ncRNAs in HCC remain unclear.

Recent studies have reported competing endogenous RNA (ceRNA) regulatory networks (ceRNET), in which ceRNAs modulate each other at the post-transcriptional level via competition of shared miRNAs. Functionally, ceRNA networks are considered the bridge to connect the functions of protein-coding mRNAs with the functions of ncRNAs, including lncRNAs, circRNAs, miRNAs and pseudogenes. According to the ceRNA hypothesis, ceRNAs sharing miRNA response elements (MREs) may affect miRNA affinity with mRNAs, thereby triggering gene silencing [11]. Because all transcripts with MREs could theoretically serve as ceRNAs, these transcripts may be considered as universal regulators of post-transcriptional events under physiological and pathological conditions. Aberrantly expressed ceRNAs may cause dysregulation of ceRNA networks, leading to human diseases, including cancer [12–14].

Several reports have demonstrated the roles of ncRNAs as ceRNAs in multiple processes of pathogenesis in HCC (Fig. 2). Based on the demonstrated function of ncRNAs as ceRNAs in HCC, ncRNAs may serve as potential biomarkers and therapeutic targets. In this review, we will discuss ncRNAs that function as ceRNAs in HCC and their relevance to current clinical practice. We first summarize the mechanisms and research methods of ceRNA and ceRNETs and provide some examples of the far-reaching roles for these molecules in affecting HCC processes. We then discuss how the basic science insights into the function of ncRNAs as ceRNAs are being applied to develop next-generation biomarkers and therapies in HCC. As the so-called “dark matter” of the genome continues to be brought into the light, it is evident that
targeting ncRNAs that function as ceRNAs and ceRNETs has great potential to impact HCC patient care.

**Mechanisms and research methods of ceRNA and ceRNETs**

Our expanded understanding of the transcriptome has led to the identification of diverse MREs in various RNA transcripts. The ceRNA hypothesis, which was initially established in 2011 [15], proposes that RNAs that share MREs can function as ceRNAs and lead to an impairment of miRNA activity (Fig. 3) [11, 16]. The upregulated expression of one particular transcript could sequester more miRNA copies from the miRNA pool and subsequently derepress other transcripts and vice versa. Moreover, the existence of MREs in IncRNAs, circRNAs and pseudogenes has suggested a modulation and control among these ncRNAs through a complicated ceRNET [17].

The in-depth studies on ceRNA interactions have revealed several potential factors for optimal ceRNA activity. First, the interaction can be affected by the abundance and relative concentration of ceRNAs and interacting miRNAs. Studies have reported that ceRNA activity reaches an optimal state when the levels of miRNA and ceRNA are nearly equimolar [18, 19]. CeRNAs have limited sequestration ability on highly abundant miRNAs; however, lowly expressed miRNAs exhibit minimal interaction with active ceRNAs due to their restricted number. Second, the location of ceRNA components is another potential factor. The expression of miRNAs is cell- and tissue-specific, and thus some ceRNAs only function in specific cells with shared accessible miRNAs [20].
Moreover, the subcellular localization of ceRNAs may also impact the availability of ceRNAs to shared miRNAs, thereby affecting ceRNA activity [21]. Third, since each miRNA can competitively bind to multiple transcripts, the binding affinities of these transcripts to miRNAs can impact the competing effects; in other words, higher affinity indicates more potent competition [22]. Of note, the binding affinity between target RNAs and miRNAs is primarily affected by the binding of MREs (located in target RNA) with seed regions (located in miRNA). Binding is additionally influenced by single-nucleotide polymorphisms, RNA editing and alternative splicing [23–26], as these factors can alter the seed regions and the target spectrum, which further lead to the production, degradation or alteration of miRNA binding sites. Fourth, the abundance of argonaute (Ago), which is the catalytic component of the RNA-induced silencing complex, is likely to be a rate-limiting factor for ceRNA crosstalk. The seed region in the RNA-induced silencing complex forms base pairs with the MREs located within the 3’-untranslated region of target RNA to modulate target RNA [27]. Finally, RNA transcripts are also likely to compete for shared RNA binding proteins, which are involved in RNA degradation, stability and splicing [28], in addition to shared miRNAs. This could hinder miRNA-target binding via MRE occupancy or inversely promote miRNA-target binding via the recruitment of miRNAs to target RNA, implicating their involvement in the ceRNET [29, 30].

The prediction, construction and validation of ceRNETs have become possible from the transcriptome data derived from various malignancies and the development of bioinformatics and computational methods. The construction of ceRNETs can effectively predict the function and underlying mechanisms of related ceRNAs. CeRNA crosstalk, a posttranscriptional event, is mediated by miRNAs and dependent on MREs located within each transcript [11]. Therefore, MRE identification in the related transcript of interest plays a decisive role in the construction of ceRNETs.
role in predicting ceRNA crosstalk. Silicon-based or high-throughput databases have been developed to facilitate the identification of ceRNETs (Table 1). The research methods and processes involving ceRNETs in HCC to date are presented in Fig. 4.

The types of ncRNAs acting as ceRNAs and their possible roles in HCC

LncRNAs as ceRNAs

LncRNAs, ncRNAs over 200 nt in length that originate from promoter-proximal, antisense and intergenic regions, carry out their regulatory function by interacting with genomic DNA, mRNAs and proteins as well as other ncRNAs [45, 46]. LncRNAs may act as sponges, scaffolds, decoys, signals and guides. LncRNAs can regulate gene expression at epigenetic, transcriptional, posttranscriptional and translational levels. Thus, these ncRNAs are considered to have pleiotropic impacts and considered “master regulators” of the genome [47, 48]. They exert regulatory effects in both physiological and pathological conditions, including in various cancers such as HCC [49–51]. Emerging evidence has revealed that a large family of lncRNAs function as ceRNAs for modulation of the expression and biological features of miRNAs in HCC [48] (Table 2).

LncRNAs can exert their functions in the HCC pathophysiological process by participating in a certain pathway but through interactions with different miRNAs. The lncRNA metastasis-associated lung adenocarcinoma transcript-1 (MALAT1) promotes HCC migration and invasion by three pathways [57–59]. First, MALAT1 competes with miR-30a-5p to regulate vimentin gene expression. Pan et al. [57] first demonstrated the sponge role of MALAT-1 for miR-30a-5p and described its functions in HCC as a ceRNA. The authors measured MALAT1 and vimentin expression levels in paired HCC and normal adjacent tissues by RT-PCR and predicted potential miR-30a-5p binding sites in MALAT1 and the target site of miR-30a-5p in vimentin using bioinformatic analyses. Co-transfection of plasmids and miR-30a-5p mimics into 293T cells was used to discover how miR-30a-5p regulates MALAT1 expression levels. Dual luciferase assay showed that miR-30a-5p significantly decreased vimentin expression level, and subsequent experiments showed that miR-30a-5p inhibits HCC cell migration and invasion. The role of MALAT1 in HCC cell growth was also tested using in vivo experiments, in which the authors injected HepG2 cells transfected with sh-MALAT1 into nude mice; the tumor volume and size in the shRNA knockdown group were smaller than that of the negative control group. These results provided in vivo evidence that MALAT1 promotes HCC growth. Second, MALAT1 competes with miR-204 to regulate SIRT1 gene expression. Hou et al. [58] used shRNA knockdown and loss-of-function strategies on MALAT1 in HepG2 cells to screen potential MALAT-1-interacting miRNA candidates, and identified miR-204 had shown

![Fig. 4](image-url)
the best correlation. The authors treated HepG2 cells with miR-204 inhibitors and mimics and found that MALAT-1 level was increased and the migration and invasion abilities of HepG2 cells were enhanced in miR-204 inhibitor group. The results demonstrated that MALAT1 derepresses SIRT1 by sponging and competitively binding to miR-204, causing enhanced migration, invasion and epithelial-mesenchymal transition (EMT) of HCC. Finally, MALAT1 also competes with miR-143-3p for the tumor suppressor ZEB1. Chen et al. [59] conducted a clinicopathological analysis in 56 paired HCC and non-tumor liver samples to explore the association between MALAT-1 expression level and clinical characteristics including age, sex, tumor size, tumor differentiation, TNM stage and distant metastasis. The authors also predicted possible interactions among MALAT1, miR-143-3p and ZEB1 based on a bioinformatics analysis. siRNA knockdown of MALAT-1 was performed in several cell lines, and Matrigel invasion assays proved that si-MALAT-1 inhibited HCC cell invasion. Subsequent experiments confirmed the existence of the MALAT1/miR-143-3p/ZEB1 regulatory pathway and showed that high expression of MALAT1 in HCC led to increased ZEB1, thus promoting the proliferation and migration of HCC.

Several lncRNAs can influence HCC behavior by several distinct mechanisms through interactions with different miRNAs and their corresponding mRNAs. HULC is one of the most upregulated lncRNAs in HCC and was found to function in HCC by at least three mechanisms (Fig. 5a). Wang et al. [12] performed chromatin accessibility by real-time PCR (CHART-PCR) assays to evaluate the accessibility of genomic DNA to nuclease and analyze different regions of open chromatin around the HULC promoter. ChIP assays demonstrated that increased euchromatic histone modifications are correlated with transcription activation of HULC. Subsequent experiments revealed significantly increased miR-372 level after siRNA-mediated inhibition of HULC, indicating that HULC decreases miR-372 expression in HCC and enhances chromatin accessibility and transcription. Li et al. [53] observed that a higher expression level of HULC in HCC tissues is associated with many enhanced EMT features.

Table 1 Summary of computational approaches for identifying the ceRNA networks

| Databases                      | Brief description                                                                 | Link                                      | Ref   |
|--------------------------------|-----------------------------------------------------------------------------------|-------------------------------------------|-------|
| starBase v2.0                  | Database supplies comprehensive interaction network of ncRNAs (lncRNAs, miRNAs, and ceRNAs), mRNA, and proteins in cancer cells and normal tissues based on 108 CLIP-Seq | http://starbase.sysu.edu.cn/             | [31]  |
| NPInter v3.0                   | Database supplies comprehensive interaction among ncRNAs (except tRNAs and rRNAs), lncRNAs and others. It provides different types of basic information about the interaction | http://www.bioinfo.org/NPInter/          | [32]  |
| DIANA-LncBase v2               | Database supplies two different miRNA–lncRNA interaction modules. One module is experimentally supported, and the other is in silico predicted interactions | http://www.microrna.gr/LncBase/           | [33, 34] |
| circBase                      | Database provides scripts to identify known and novel circRNAs in sequencing data. | http://www.circbase.org/                 | [35]  |
| LNCediting                     | Database supplies information about RNA editing in lncRNAs and miRNA–lncRNA interactions | http://bioinfo.life.hust.edu.cn/LNCediting/ | [36]  |
| CircInteractome                | Database supplies information about circRNAs and their interaction with proteins or miRNAs | http://circinteractome.nia.nih.gov/      | [37]  |
| Cancer-Specific-CirRNA-Database (CSCD) | Database for cancer-specific circRNAs                                            | http://gb.whu.edu.cn/CSCD/              | [38]  |
| spongeScan                     | Database supplies information about microRNA binding elements in lncRNA sequences | http://spongescan.rc.ufl.edu             | [39]  |
| SomamiR 2.0                    | Database provides information and functional analysis of expected miRNA–lncRNA interaction | http://compbio.uthsc.edu/SomamiR        | [40]  |
| IncCeDB                        | Database provides information of human lncRNA that acts as ceRNAs                | http://gyanxet-beta.com/Incedb/         | [41]  |
| miRBase                        | Database provides miRNA gene hunters with unique names for novel miRNA genes prior to publication of results | http://www.mirbase.org/                 | [42]  |
| Targetscan                     | Database provides information of predicted microRNA targets                      | http://www.targetscan.org/vert_72/     | [43]  |
| miRcode                        | Database provides “whole transcriptome” human microRNA target predictions based on the comprehensive GENCODE gene annotation. | http://www.mircode.org/                 | [44]  |

ncRNA: noncoding RNA; ceRNA: competing endogenous RNA; lncRNA: long noncoding RNA; mRNAs: messenger RNAs; miRNA: microRNA; circRNA: circularRNA; Ref: reference
| ceRNA network type | ceRNA member | Shared miRNA(s) | Competing target (mRNA) | ceRNA role | Experiments related to mechanism | Related HCC function mechanisms | Ref |
|--------------------|--------------|-----------------|--------------------------|------------|---------------------------------|-------------------------------|-----|
| LncRNA–miRNA–mRNA  | HULC         | miR-372, miR-6825-5p, miR-6845-5p, miR-6886-3p | PRKACB, USP22, ZEB1, HMGA2 | Oncogenic | Cellular, shRNA knockdown in mouse xenografts, siRNA knockdown in mouse xenografts, Overexpression, antisense in mouse xenografts | Invasion and metastasis, Chemosensitivity, Invasion and EMT | [12], [52], [53], [54] |
|                    |              |                 |                          |            |                                 |                               |     |
|                    |              | miR-200a-3p     | ZEB1                     | Oncogenic  |                                 |                               |     |
|                    |              |                 |                          |            |                                 |                               |     |
|                    |              | miR-186         | HMGA2                    | Oncogenic  | Overexpression, antisense in mouse xenografts | Proliferation                 | [54] |
|                    |              |                 |                          |            |                                 |                               |     |
| HOTAIR             | miR-122      | DNMTs           | Oncogenic                | Oncogenic  | shRNA knockdown in mouse xenografts | Proliferation                 | [55] |
|                    |              |                 |                          |            |                                 |                               |     |
|                    | miR-23b-3p   | ZEB1            | Oncogenic                | Oncogenic  | Overexpression                  | Invasion and EMT              | [56] |
|                    |              |                 |                          |            | in mouse xenografts             |                               |     |
| MALAT1             | miR-30a-5p   | Vimentin        | Oncogenic                | Oncogenic  | shRNA knockdown in mouse xenografts | Migration and invasion        | [57] |
|                    |              |                 |                          |            |                                 |                               |     |
|                    | miR-204      | SIRT1           | Oncogenic                | Oncogenic  | Cellular                        | Migration and invasion        | [58] |
|                    |              |                 |                          |            |                                 |                               |     |
|                    | miR-143-3p   | ZEB1            | Oncogenic                | Oncogenic  | Cellular                        | Proliferation and invasion    | [59] |
|                    |              |                 |                          |            |                                 |                               |     |
| MIAT               | miR-214      | EZH2            | Oncogenic                | Oncogenic  | siRNA knockdown in mouse xenografts | Proliferation and invasion    | [60] |
|                    |              |                 |                          |            |                                 |                               |     |
| LINC00974          | miR-642      | KRT19           | Oncogenic                | Oncogenic  | shRNA knockdown in mouse xenografts | Proliferation and metastasis  | [61] |
|                    |              |                 |                          |            |                                 |                               |     |
| CCAT1              | Let-7        | HMGA2, c-Myc    | Oncogenic                | Oncogenic  | Cellular                        | Proliferation and migration   | [62] |
|                    |              |                 |                          |            |                                 |                               |     |
| DANCR              | miR-214, miR-320a, miR-199a | CTNNB1 | Oncogenic                | Oncogenic  | siRNA knockdown in mouse xenografts | Invasion and metastasis       | [63] |
|                    |              |                  |                          |            |                                 |                               |     |
|                    | miR-27a-3p   | ROCK1, LIMK1, COFILIN1 | Oncogenic                | Oncogenic  | shRNA knockdown in mouse xenografts | Proliferation and metastasis  | [64] |
|                    |              |                  |                          |            |                                 |                               |     |
|                    | miR-216a-5p  | KLF12           | Oncogenic                | Oncogenic  | shRNA knockdown in mouse xenografts | Migration and invasion        | [65] |
|                    |              |                  |                          |            |                                 |                               |     |
| HOTTIP             | miR-125b     | HOXA            | Oncogenic                | Oncogenic  | shRNA knockdown in mouse xenografts | Proliferation and migration   | [66] |
|                    |              |                  |                          |            |                                 |                               |     |
| ATB                | miR-200 family | ZEB1, ZEB2     | Oncogenic                | Oncogenic  | Overexpression, knockdown in mouse xenografts | Invasion and EMT              | [67] |
|                    |              |                  |                          |            |                                 |                               |     |
| UCA1               | miR-216b     | FGFR1           | Oncogenic                | Oncogenic  | siRNA knockdown in mouse xenografts | Proliferation and metastasis  | [68] |
|                    |              |                  |                          |            |                                 |                               |     |
|                    | miR-203      | Snail2          | Oncogenic                | Oncogenic  | shRNA knockdown in mouse xenografts | Proliferation and invasion    | [69] |
|                    |              |                  |                          |            |                                 |                               |     |
| FAL1               | miR-1236     | AFP, ZEB1       | Oncogenic                | Oncogenic  | Cellular                        | Proliferation and migration   | [70] |
| ceRNA network type | ceRNA member | Shared miRNA(s) | Competing target (mRNA) | ceRNA role | Experiments related to mechanism | Related HCC function mechanisms | Ref |
|------------------|-------------|----------------|-------------------------|------------|---------------------------------|-------------------------------|-----|
| MUF              | miR-34a     |                | Snail1                  | Oncogenic  | overexpression in mouse xenografts | EMT                           | [71]|
| HOXD-AS1         | miR-130a-3p |                | SOX4                    | Oncogenic  | shRNA knockdown in mouse xenografts | Migration and invasion         | [72]|
| SNHG8            | miR-149-5p  |                | PPM1F                   | Oncogenic  | shRNA knockdown in mouse xenografts | Proliferation and metastasis  | [73]|
| CDKN2B-AS1       | let-7c-5p   |                | NAP1L1                  | Oncogenic  | shRNA knockdown in mouse xenografts | Proliferation and metastasis  | [74]|
| FLVCR1-AS1       | miR-513c    |                | MET                     | Oncogenic  | shRNA knockdown in mouse xenografts | Proliferation, migration and invasion | [75]|
| ZFAS1            | miR-150     |                | ZEB1, MMP14, MMP16      | Oncogenic  | Overexpression, shRNA knockdown in mouse xenografts | Proliferation and metastasis  | [76]|
| NEAT1            | miR-485     |                | STAT3                   | Oncogenic  | Cellular                         | Migration and invasion         | [77]|
| TUG1             | miR-142-3p  |                | ZEB1                    | Oncogenic  | shRNA knockdown in mouse xenografts | Proliferation and EMT           | [78]|
|                 | miR-144     |                | JAK2                    | Oncogenic  | shRNA knockdown in mouse xenografts | Proliferation and migration    | [79]|
| ANRIL            | miR-122-5p  |                | NR                      | Oncogenic  | shRNA knockdown in mouse xenografts | Proliferation and metastasis  | [80]|
| n335586          | miR-924     |                | CKMT1A                  | Oncogenic  | Overexpression in mouse xenografts | Migration and invasion         | [81]|
| HOXA-AS2         | miR-520c-3p |                | GPC3                    | Oncogenic  | shRNA knockdown in mouse xenografts | Proliferation and EMT           | [82]|
| PCAT-1           | miR-215     |                | CRKL                    | Oncogenic  | shRNA knockdown, miR upregulation in mouse xenografts | Proliferation                 | [83]|
| MCM3AP-AS1       | miR-194-5p  |                | FOXA1                   | Oncogenic  | shRNA knockdown in mouse xenografts | Proliferation                 | [84]|
| SNHG6-003        | miR-26a/b   |                | TAK1                    | Oncogenic  | Overexpression in mouse xenografts | Proliferation                 | [85]|
| TP73-AS1         | miR-200a    |                | HMGB1, RAGE             | Oncogenic  | Overexpression, shRNA knockdown in mouse xenografts | Proliferation                 | [86]|
| DSCR8            | miR-485-5p  |                | FZD7                    | Oncogenic  | Overexpression, shRNA knockdown in mouse xenografts | Proliferation                 | [87]|
| LINC00707        | miR-206     |                | CDK14                   | Oncogenic  | shRNA knockdown in mouse xenografts | Proliferation, migration and invasion | [88]|
| AGAP2-AS1        | miR-16-5p   |                | ANXA11                  | Oncogenic  | Overexpression, shRNA knockdown in mouse xenografts | Proliferation and metastasis  | [89]|
including histological morphology, physiological behavior and EMT markers such as E-cadherin, N-cadherin, ZO-1, vimentin, β-catenin, Snail and ZEB1. The authors proposed that HULC exhibits a negative regulatory effect on miR-200a-3p and upregulates ZEB1, resulting in enhanced EMT and promoted growth and metastasis of HCC. A HULC/USP22/Sirt1 protective autophagy pathway was further identified that attenuates HCC cell sensitivity to chemotherapeutic agents [52]. In the study, autophagy-related proteins were markedly increased upon HULC overexpression, but were significantly reduced upon Sirt-1 silencing. These results revealed a HULC-Sirt1-autophagy pathway, which was further discovered to be able to weaken the chemosensitivity of HCC cells toward oxaliplatin.

Table 2 (continued)

| ceRNA network type | ceRNA member | Shared miRNA(s) | Competing target (mRNA) | ceRNA role | Experiments related to mechanism | Related HCC function mechanisms | Ref |
|--------------------|--------------|-----------------|-------------------------|------------|----------------------------------|---------------------------------|-----|
| mat                | miR-22-3p    | sirt1           | Oncogenic               | Knockdown in mouse xenografts | Proliferation                  | [90]                            |
| DSCAM-AS1          | miR-338-3p   | CyclinD1, SMO    | Oncogenic               | shRNA knockdown in mouse xenografts | Proliferation, migration and invasion | [91]                            |
| XIST               | miR-194-5p   | MAPK1           | Oncogenic               | shRNA knockdown in mouse xenografts | Proliferation, migration and invasion | [92]                            |
|                    | miR-497-5p   | PDCD4           | Tumor suppressive       | Overexpression in mouse xenografts | Proliferation and metastasis   | [93]                            |
|                    | miR-92b      | Smad7           | Tumor suppressive       | Overexpression, knockdown in mouse xenografts | Proliferation and metastasis   | [94]                            |
| LINC00657          | miR-106a-5p  | PTEN            | Tumor suppressive       | shRNA knockdown in mouse xenografts | Proliferation, migration and invasion | [95]                            |
| MEG3               | miR-9-5p     | SOX11           | Tumor suppressive       | Cellular                                             | Proliferation                   | [96]                            |
| SNHG16             | miR-93       | NR              | Tumor suppressive       | Overexpression in mouse xenografts                  | Cell proliferation and chemosensitivity | [97]                            |
| CASC2              | miR-367      | FBXW7           | Tumor suppressive       | Overexpression downregulation in mouse xenografts   | EMT                             | [98]                            |
| MIR31HG            | miR-575      | ST7L            | Tumor suppressive       | shRNA knockdown in mouse xenografts                  | Proliferation and metastasis   | [99]                            |
| FTX                | miR-374a     | WIFI, PTEN, WNT5A | Tumor suppressive       | Overexpression in mouse xenografts                  | Invasion and EMT                | [100]                           |

ceRNA: competing endogenous RNA; lncRNA: long noncoding RNA; miRNAs: messenger RNAs; miRNA: microRNA; HCC: hepatocellular carcinoma; EMT: epithelial–mesenchymal transition; Ref: reference.

Together, these studies on the associations between lncRNAs and HCC show that lncRNAs function in a multidimensional network to influence HCC, not only by interacting with a large group of miRNAs and affecting their correlated pathways, but also by participating in a number of distinct mechanisms. Notably, some lncRNAs show both tumor suppressive and oncogenic functions, which calls for additional studies to determine how these seemingly contrary functions are balanced and regulated.

CircRNAs as ceRNAs

CircRNAs are relatively more resistant to degradation compared with linear RNA because the 3′ and 5′ ends of circRNAs are covalently linked [101]. Apart from higher stability compared with linear RNAs, circRNAs are highly homologous to their linear counterparts and

pathway, but promotes HCC progression by silencing miR-194-5p and derepressing MAPK1 [92–94].
Fig. 5 Simplified examples of the roles that different classes of ceRNAs play in HCC oncogenesis. **a** LncRNA: HULC functions in HCC by three mechanisms: (1) Transcription activation of HULC decreases miR-372 level in HCC, derepresses PRKACB function and CREB phosphorylation, hence enhancing chromatin accessibility and transcription. (2) HULC exerts a negative regulatory effect on miR-200a-3p and subsequent upregulation of ZEB1, which facilitates EMT, tumor growth and metastasis. (3) HULC sponges miR-6825-5p, miR-6845-5p and miR-6886-3p, leading to increased expression of USP22 and Sirt1, which activates the protective autophagy pathway and attenuates HCC cell sensitivity to chemotherapeutic agents. **b** CircRNA: CircASAP1 decreases miR-326 and miR-532-5p level, thus promoting proliferation and invasion of HCC through miR-326/MAPK/ERK1/2 signaling, and raising TAMs infiltration through CSF-1 activation and secretion. **c** Pseudogene: RACGAP binds to miR-15, enhances the binding of GTP to RhoA and further ERK phosphorylation, promoting tumor cell proliferation and migration.
contain more MREs. Thus, circRNAs can act as effective miRNA sponges to disrupt miRNA-mediated target repression and regulate genes at both transcriptional and post-transcriptional levels as robust ceRNAs [102]. Emerging evidence has demonstrated that circRNAs may counteract miRNA-mediated repression of linear mRNAs by functioning as miRNA sponges (Table 3).

Similar to other ceRNAs, circRNAs competitively inhibit miRNAs via their MREs. CircRNAs function in tumor signaling pathways through their regulation of cell proliferation, apoptosis, tumor invasion and migration. Qin et al. [142] demonstrated significantly decreased expression of has_circ_0001649 expression in HCC tissues (P = 0.0014), which was related to tumor embolus (P = 0.017) as well as tumor size (P = 0.045). Yao et al. [143] reported the significantly decreased expression of circZKSCAN1 (hsa_circ_0001727) in HCC (P < 0.05), which was associated with vascular invasion (P = 0.002) and cirrhosis (P = 0.031) as well as tumor number (P < 0.01). Hu et al. reported increased levels of circASAP1 in HCC patients with postoperative metastasis or recurrence [103]. Transplanted HCC mouse models verified that circASAP1 promoted proliferation as well as invasion of HCC through miR-326/miR-532-5p-MAPK signaling (Fig. 5b). Xenografts of tumors with shRNA-mediated knockdown of circASAP1 showed decreased numbers of metastatic pulmonary nodules, while the xenograft model derived from circASAP1-overexpressing cells had a higher rate of lung metastasis. In addition, circASAP1 enhanced the infiltration of tumor-associated macrophages in xenografts, but no alterations of infiltrating neutrophils or fibroblasts were observed. Zhang et al. observed that overexpression of circSMAD2 attenuated invasion, migration and EMT of HCC by sponging miR-629 [139]. Taken together, these results provide evidence that circRNAs have a dual role in regulating tumor signaling pathways by competing with miRNAs with contrary functions.

CircRNAs are resistant to exonucleases, resulting in relatively stable expression and intracellular accumulation. Exosomal excretion is thus an important route of in vivo elimination of circRNAs. In a study by Su et al., SMMC-7721 and HepG2 cell-derived exosomal circRNA Cdr1 was transfected into 293T cells [104]. Consistent with its intracellular function, exosomal Cdr1as increased the proliferation and migration of 293T cells, indicating that circRNAs function in the cytoplasm and exosomes. Zhang et al. reported a similar finding in the circ-DB/miR-34a/USP7/Cyclin A2 pathway [114].

The activating receptor natural-killer group 2 member D (NKG2D) is a tumor-associated immune response marker, and its expression indicates immune response mediated by CD8+T cells and γδ+T cells as well as NK cells in tumors. Zhang et al. proposed the circTRIM22-12/miR-191/TET1 pathway and validated it in circTRIM33-12-overexpressing nude mice xenograft models. circTRIM33-12 expression level was positively correlated with NKG2D-positive cell numbers in HCC, suggesting that circTRIM33-12 sponged miR-191/TET1 and exerted an anti-tumor function by not only participating in the tumor proliferation–related signaling pathway, but also contributing to immune surveillance and T cell activation [136].

Considering the high stability of circRNAs in body fluids, including blood and saliva, circRNAs are potential superior biomarkers for HCC diagnosis. The miR-328-3p/HIF1AN-NOTCH2 and miR-892a/HDGF-NCL-PI3K-AKT pathways regulated by circCDYL facilitate Survivin and Myc expression in HCC, suggesting that a combination of circCDYL, HIF1AN and HDGF can be used for the diagnosis of Barcelona Clinic Liver Cancer stage 0 and A of HCC [144]. CircRNA_104075, another potential diagnostic biomarker, was discovered to upregulate the expression of YAP by inhibiting miR-582-3p. Zhang et al. used the CRISPR/Cas9 strategy to establish a knockdown mouse model of HNF4a. HNF4a was formerly proved to be an HCC-promoting transcription promoter. HNF4a knockout mice were smaller in size, with a low liver weight, and had low expression of circ_104075, which indicates that circ_104075 transcription is stimulated by HNF4a. Intriguingly, an m6A modification in the 3′-untranslated region of YAP mRNA facilitates the interaction between YAP, miR-582-3p and circRNA_104075, demonstrating how circRNA function can be influenced by methylation or other modifications and the role of epigenetics in circRNA function [108].

Similar to lncRNAs, circRNAs exert their diverse functions in HCC through sponging miRNAs. CircRNAs exhibit multiple roles in different pathways and participate in HCC pathogenesis through various pathophysiological processes. In addition, circRNAs show enhanced stability, making them promising candidates for novel cancer biomarkers.

**Pseudogenes as ceRNAs**

Pseudogenes were previously described as non-functional, genomic junk DNAs sharing homology with the parental encoding sequence. Pseudogenes were characterized by a loss of protein-coding regions due to truncation or mutation and suggested to have no function. Transcriptomic and proteomic analyses have not only confirmed the ability of pseudogenes to produce transcripts and proteins, but also revealed novel miRNA/gene/pseudogene regulatory networks in cancer biology [145, 146]. Studies on the influence of pseudogenes
| ceRNA network type | ceRNA member | Shared miRNA(s) | Competing target (mRNA) | ceRNA role | Experiments related to mechanism | Related HCC function mechanisms | Ref |
|--------------------|--------------|-----------------|--------------------------|------------|---------------------------------|--------------------------------|-----|
| CircRNA–miRNA–mRNA | circASAP1    | miR-326, miR-532-5p | MAPK1, CSF-1              | Oncogenic  | Overexpression, shRNA knockdown in mouse xenografts | Proliferation and invasion   | [103] |
|                    | circCdr1as   | miR-1270        | AFP                      | Oncogenic  | Cellular                         |                                | [104] |
|                    | circCdr1as   | miR-7           | CCNE1, PIK3CD            | Oncogenic  | Cellular                         |                                | [105] |
|                    | circABCC2    | miR-665         | ABCC2                    | Oncogenic  | siRNA knockdown in mouse xenografts | Proliferation and invasion   | [106] |
|                    | circ_104718  | miR-218-5p      | TXNDC5                   | Oncogenic  | overexpression, siRNA knockdown in mouse xenografts, miR mimics, miR inhibitors | Proliferation, migration and invasion | [107] |
|                    | circ_104075  | miR-582-3p      | YAP                      | Oncogenic  | CRISPR/Cas9 knockout of upstream positive regulator in mouse models | Proliferation                | [108] |
|                    | circFBLIM1   | miR-346         | FBLIM1                   | Oncogenic  | siRNA knockdown in mouse xenografts | Proliferation and invasion   | [109] |
|                    | circ_100338  | miR-141-3p      | RHEB                     | Oncogenic  | Cellular                         | Migration and invasion       | [110] |
|                    | circ_0067934 | miR-1324        | FZD5                     | Oncogenic  | siRNA knockdown in mouse xenografts | Proliferation, migration and invasion | [111] |
|                    | circ_0078710 | miR-31          | HDAC, CDK2               | Oncogenic  | Overexpression in mouse xenografts | Proliferation, migration and invasion | [112] |
|                    | circ_CDYL    | miR-892a, miR-328-3p | HDGF, HIF1AN             | Oncogenic  | shRNA knockdown in mouse xenografts | Proliferation and chemoresistance | [113] |
|                    | circ_DB      | miR-34a         | USP7                     | Oncogenic  | Overexpression, shRNA knockdown in mouse xenografts | Proliferation                | [114] |
|                    | circ_101368  | miR-200a        | HMGB1, RAGE              | Oncogenic  | Cellular                         | Migration and invasion       | [115] |
|                    | circ_001569  | miR-411-5p, miR-432-5p | –                       | Oncogenic  | shRNA knockdown in mouse xenografts | Migration and invasion       | [116] |
|                    | circ_0015756 | miR-7           | FAK                      | Oncogenic  | shRNA knockdown in mouse xenografts | Proliferation, migration and invasion | [117] |
|                    | circRBM23    | miR-138         | CCND3                    | Oncogenic  | Overexpression, shRNA knockdown in mouse xenografts | Proliferation and migration  | [118] |
|                    | circ_0016788 | miR-486         | CDK4                     | Oncogenic  | shRNA knockdown in mouse xenografts | Proliferation and invasion   | [119] |
|                    | circ_0000673 | miR-767-3p      | SET                      | Oncogenic  | siRNA knockdown in mouse xenografts | Proliferation and invasion   | [120] |
Table 3 (continued)

| ceRNA network type | ceRNA member | Shared miRNA(s) | Competing target (mRNA) | ceRNA role | Experiments related to mechanism | Related HCC function mechanisms | Ref |
|--------------------|--------------|-----------------|--------------------------|------------|----------------------------------|--------------------------------|-----|
| circ_0005075       | miR-431      | ———            | Oncogenic                | Cellular   | Proliferation, migration and invasion | [121] |
|                    | miR-335      | MAPK1           | Oncogenic                | siRNA knockdown in mouse xenografts | Proliferation, migration and invasion | [122] |
| circ_BIRC6         | miR-3918     | Bcl2            | Oncogenic                | Overexpression, shRNA knockdown in mouse xenografts | Proliferation, migration and invasion | [123] |
| circ_ZNF652        | miR-203, miR-502-5p | Snail | Oncogenic                | Knockdown in mouse xenografts | EMT | [124] |
| circ_ZFR           | miR-3619-5p  | CTNNB1          | Oncogenic                | Cellular   | Proliferation and EMT | [125] |
| circ_0008450       | miR-214-3p   | EZH2            | Oncogenic                | siRNA knockdown in mouse xenografts | Proliferation, migration and invasion | [126] |
| circ_0000517       | miR-326      | SMAD6           | Oncogenic                | shRNA knockdown in mouse xenografts | Proliferation, colony formation, migration, and invasion | [127] |
| circNFATC3         | miR-548i     | NFATC3          | Tumor suppressive        | shRNA knockdown in mouse xenografts | Proliferation, migration and invasion | [128] |
| circ_103809        | miR-620      | ———            | Tumor suppressive        | Cellular   | Proliferation and EMT | [129] |
| circC3P1           | miR-4641     | PCK1            | Tumor suppressive        | Overexpression in mouse xenografts, miR mimics | Proliferation, migration and invasion | [130] |
| circ_0091570       | miR-1307     | ISM1            | Tumor suppressive        | Overexpression, siRNA knockdown in mouse xenografts | Proliferation and migration | [131] |
| circ_0001649       | miR-127-5p, miR-612, miR-4688 | SHPRH | Tumor suppressive        | shRNA knockdown in mouse xenografts | Proliferation and migration | [132] |
| circMTO1           | miR-9        | p21             | Tumor suppressive        | siRNA knockdown in mouse xenografts | Proliferation and migration | [133] |
| cSMARCA5           | miR-17-3p, miR-181b-5p | TIMP3 | Tumor suppressive        | Overexpression in mouse xenografts | Proliferation and migration | [134] |
| circSETD3          | miR-421      | MAPK-14         | Tumor suppressive        | Overexpression in mouse xenografts | Proliferation | [135] |
| circTRIM33-12      | miR-191      | TET1            | Tumor suppressive        | Overexpression, shRNA knockdown in mouse xenografts | Proliferation, migration, invasion and immune evasion | [136] |
| circADAMTS13       | miR-484      | ADAMTS13        | Tumor suppressive        | Cellular   | Proliferation | [137] |
| circADAMTS14       | miR-572      | RCAN1           | Tumor suppressive        | Overexpression in mouse xenografts, miR mimics, miR inhibitors | Proliferation and invasion | [138] |
in different types of tumors have revealed their roles in HCC (Table 4).

OCT4-pg4 is a pseudogene related to OCT4, a transcription factor that is involved in proliferation, pluripotency and self-renewal ability in embryonic stem cells and germ cells [149]. The expression of OCT4-pg4 is positively associated with OCT4, and both are increased in HCC. Wang et al. found that OCT4-pg4 serves as a molecular decoy towards miR-145 and prevents OCT4 inhibition, thus promoting HCC growth and tumorigenicity [10]. Survival analysis of 54 cases of HCC suggested a significant correlation between increased OCT4-pg4 expression levels and shortened overall survival as well as disease-free survival in HCC patients.

RACGAP, a member of the GTPase activation family, is an oncoprotein that enhances the proliferation and migration of HCC by activating the RhoA/ERK signaling pathway. The RACGAP gene is also the first gene reported as an independent biomarker for HCC recurrence. Wang et al. discovered the significant up-regulation of the RACGAP1P pseudogene in HCC, which was related to shortened survival, larger tumor size, elevated AFP level and advanced clinical stage [147]. Luciferase assays and in vivo assays demonstrated that miR-15-5p was sequestered from its endogenous target RACGAP by RACGAP1P, causing increased RACGAP expression and contributing to the RACGAP oncogenic network (Fig. 5c).

In addition to oncogenic pseudogenes, tumor suppressive pseudogenes have also been identified. The INTS6 pseudogene inhibits the tumor growth in several types of human cancers through G1 cell cycle arrest. Peng et al. showed that INTS6 inhibited HCC cell growth, migration and survival [148]. Furthermore, INTS6P1 facilitated tumor suppression by competing with oncogenic miR-17-5p. In vitro and in vivo assays also showed that both INTS6 and INTS6P inhibited HCC cell growth, migration and survival.

These studies indicate that pseudogenes serve as ceRNAs and affect tumorigenesis through ceRNets. With respect to their role in HCC carcinogenesis, pseudogenes may be used as prognostic indicators, stratification factors or therapeutic targets, and these functions may lead to the development of precise and individualized therapeutic strategies for HCC. It is likely that HCC-associated pseudogenes acting as ceRNAs are rare. Nevertheless, with the widespread application of whole-genome high-throughput sequencing technology, we believe that more HCC-associated pseudogenes will be uncovered and applied in disease management.
The clinical application of ncRNAs as ceRNAs in HCC

The current commonly used screening methods for HCC include the alpha-fetoprotein (AFP) diagnostic marker, ultrasonography, computed tomography, magnetic resonance imaging and liver biopsy [150]. Among these methods, imaging examination and serum AFP testing are the most common and basic screening approaches. However, even if a low-level cutoff is applied, the sensitivity value of AFP for diagnosing HCC is nearly 60% and the specificity is still inadequate [151]. Moreover, approximately 30% of patients with early-stage HCC cannot be detected using serum AFP as diagnostic biomarker [3]. According to the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) guidelines for HCC, serum AFP level can also be used to monitor HCC progression [152, 153]. Although the diagnostic rate of HCC has markedly increased from the adoption of serum AFP screening, the limited specificity of serum AFP has led to overdiagnosis and overtreatment [154]. In treating HCC patients with antineoplastic drugs, currently available regimens have shown disappointing results: both first-line therapy sorafenib and lenvatinib only prolong survival by nearly two months for patients with advanced-stage HCC [155]. Given the emerging evidence indicating that ncRNAs act as ceRNAs and suggesting their use as biomarkers and even therapeutic targets for HCC, further studies on ncRNAs may provide new insights and novel strategies for HCC diagnosis, surveillance and treatments.

Potential diagnostic biomarkers in HCC

Several ncRNAs that act as ceRNAs have been identified in the circulation and other body fluids in HCC and other cancers [108, 156–158]. These results suggested the potential that ncRNAs that act as ceRNAs and their associated ceRNETs may be useful for clinical applications as diagnostic biomarkers of HCC (Table 5).

Ming et al. demonstrated that the lncRNA BCYRN1 functions as a ceRNA to play a vital role in HCC [159]. The authors analyzed BCYRN1 expression in plasma from 124 HCC patients, 79 cirrhosis patients, 68 hepatitis B patients and 74 healthy controls. Plasma BCYRN1 expression of HCC patients was significantly higher than that of healthy controls (p < 0.001) or hepatitis B patients (p < 0.01) [159]. Furthermore, combined detection of

| Table 5 | Potential clinical application of ncRNAs function as ceRNAs in HCC |
|---------|-------------------------------------------------------------|
| ncRNA as ceRNA | Location | Clinical application | Description | Ref |
| circRNA_104075$^*$ | Serum | Diagnosis | AUC: 0.973, Se: 96.0%, Sp: 98.3% | [108] |
| BCYRN 1$^*$ | Serum | Diagnosis, prognosis, potential therapeutic target | Diagnosis: AUC: 0.7834, Se: 62.10%, Sp: 90.54%; Prognosis: overexpression associates with worse prognosis | [159, 160] |
| IncRNA-RP11-51315.6, mir-1262, RAB11A$^T$ | Serum | Diagnosis | AUC: NA, Se: 100%, Sp: 76.7% | [156] |
| OCT4-pg4$^T$ | Tissue | Prognosis, potential therapeutic target | Associates with prognosis | [10] |
| HOXD-AS1$^*$ | Tissue | Prognosis, potential therapeutic target | Associates with TNM stage and prognosis | [72] |
| SNHG6-003$^*$ | Tissue | Prognosis, potential therapeutic target | Associates with portal vein tumor thrombus, BCLC stage, distant metastasis and prognosis | [85] |
| AGAP2-AS1$^*$ | Tissue | Prognosis, potential therapeutic target | Associates with tumor size, histological grade, TNM stage, venous invasion and prognosis | [89] |
| CASC2$^*$ | Tissue | Prognosis, potential therapeutic target | Associates with venous infiltration, histological grade, TNM stage and prognosis | [98] |
| circRNA_104718$^T$ | Tissue | Prognosis, potential therapeutic target | Associates with vascular invasion and prognosis | [107] |
| circ_0000517$^T$ | Tissue | Prognosis, potential therapeutic target | Associated with tumor size, TNM stage, lymph node metastasis and prognosis | [127] |
| circNfatc3$^T$ | Tissue | Prognosis, potential therapeutic target | Associates with vascular invasion, histological grade and prognosis | [128] |
| MYCNOS, DLX6-AS1, LINC00221, CRNDE$^*$ | Tissue | Prognosis | Associates with prognosis | [161] |
| 13 IncRNAs prognostic model$^T$ | Tissue | Prognosis | Associates with prognosis | [162] |
| 3 IncRNAs and 6mRNAs prognostic model$^T$ | Tissue | Prognosis | Associates with prognosis | [163] |

ncRNA: non-coding RNA; ceRNA: competing endogenous RNA; HCC: hepatocellular carcinoma; AUC: Area under the curve; Se: Sensitivity; Sp: Specificity; NA: Not available; BCLC: Barcelona Clinic Liver Cancer; Ref: reference

$^*$ Long non-coding RNA; $^T$ circular RNA; $^\dagger$ pseudogene; $^\ddagger$ ceRNA panel
Potentially prognostic biomarkers and therapeutic targets in HCC

Several studies have explored the clinical application of ncRNAs that function as ceRNA as prognostic biomarkers and potential therapeutic targets for HCC (Table 5). Cao et al. found that the IncRNA SNHG6-003 functions as a ceRNA to promote cell proliferation and induce drug resistance in HCC [85]. High expression of SNHG6-003 expressed in patient tumors with a correlation to tumor progression and poor survival in HCC patients. The results suggested that targeting the ceRNA network involving SNHG6-003 may be a treatment strategy against HCC. Besides the tremendous diagnostic value in HCC, the prognostic value of BCYRN1 was also proven in a recent study. Ding et al. demonstrated that overexpression of BCYRN1 significantly expedited HCC cell growth, clone formation, and movement abilities, while downregulation of BCYRN1 had the opposite effects [160]. The authors also found that BCYRN1 was overexpressed in HCC samples, which was associated with unfavorable prognosis in patients with HCC. The study findings indicated that BCYRN1, miR-490-3p, and POU3F2 formed a ceRNA mechanism to modulate the occurrence and progression of HCC, suggesting these can be served as potential target molecules for the management of HCC [160]. Recently, Lin et al. established a circRNA-miRNA-mRNA regulatory network by integrating the analysis of differentially expressed circRNAs, miRNAs and mRNAs in HCC [9]. The functional enrichment analysis of differentially expressed circRNA-related miRNAs, screened from the constructed HCC-associated ceRNETs, revealed that differentially expressed circRNAs were significantly associated with cell proliferation, cell adhesion and cell migration. The differentially expressed circRNAs are involved in various processes including cell cycle, peroxisome proliferator-activated receptor signaling, chemical carcinogenesis and p53 signaling, playing vital roles in HCC progression. The refined circRNA-miRNA-mRNA regulatory modules associated with HCC carcinogenesis further uncovered three key circRNAs (hsa_circ_0004913, hsa_circ_0007456 and hsa_circ_0078279) that may play important roles in carcinogenesis and progression of HCC [9]. These circRNAs may competitively bind to miR-182 and miR-346 to affect their respective regulatory networks. Functionalization of previously uncharacterized transcripts could be achieved, partially by identifying the ceRNA interactors, to present a framework for predicting and validating ceRNA interactions; this strategy may be universally applied to any transcript. In a scale-free network, links between nodes follow a power-law distribution, which suggests that most nodes have only a few links, while a few nodes can possess a large number of links [164]. These post-transcriptional ceRNETs can be considered as scale-free networks, because their structure is constructed upon smaller interconnected subnetworks, in which the nodes (ceRNAs) are linked by a large number of connections (miRNAs) [11]. The few highly connected nodes, also known as target hubs, were found to be critically involved in biological processes [164]. Therefore, these critical nodes (three circRNAs and two miRNAs), identified by the constructed circRNA-associated ceRNETs, may represent ideal therapeutic targets for HCC.

As promising biomarkers in the screening, diagnosis and prognosis for HCC, ncRNAs as ceRNAs are also potential therapeutic targets. However, there are still significant gaps in our current understanding of ncRNA functions as ceRNAs and we are still far from being able to incorporate ncRNAs into clinical practice. Large-scale studies and clinical trials are required to validate the role of ncRNAs as ceRNAs in the clinical application for HCC.

Conclusions

In this review, we briefly discussed ceRNAs as well as the principles and influencing factors of the interactions between ceRNAs, concentrating on the roles and molecular mechanisms of ncRNAs that function as...
ceRNAs in HCC. We also summarized the ideas and methods to study ceRNAs and ceRNETs in HCC and some commonly used databases.

Recently, significant progress has been made in the studies of ceRNAs in HCC. To date, studies on ncRNAs that act as ceRNAs in HCC have primarily involved overexpression and knockdown assays in cells and animals. However, ceRNA activity is affected by other factors, including subcellular location and ceRNA component abundance, interactions with RNA binding proteins, RNA editing and ceRNA affinity in the endogenous cellular context. Whether the results shown in overexpression assays truly reflect the spontaneous ceRNA crosstalk during carcinogenesis in patients with HCC remains unknown. Therefore, more animal experiments and clinical trials should be performed to validate these results.

Additionally, the majority of identified ceRNA interactions reflect single binding partners, although emerging evidence indicates ceRNA crosstalk in large interconnected networks. Aside from direct interactions via shared miRNAs, secondary and indirect interactions might also exert significant effects on ceRNA modulation. Thus, further investigations of ceRNAs should not only concentrate on identifying binary ceRNA interactions but enroll network analyses of potential complex miRNA and ceRNA networks. Moreover, the scale-free network property of ceRNA regulation also poses a challenge in selecting HCC-related molecular therapeutic targets. Targeting nonessential nodes within regulatory networks could cause ineffective therapeutic responses, as cancer cells may overcome the resulting damage through alternative signaling pathways. Therefore, the selection of therapeutic targets situated in a hub position of a ceRNET should be considered in future screening studies for HCC therapeutic targets.

In summary, the recently developed research techniques and computational approaches as well as the continued uncovering of ceRNET components will facilitate more detailed studies of ncRNAs that act as ceRNAs in HCC. These findings will not only provide a more comprehensive understanding of the underlying mechanism of HCC pathogenesis and progression but also establish a novel direction for future strategies for the diagnosis, treatment and prevention of HCC.

Acknowledgements
We gratefully acknowledge all of the other researchers and work in this field that we were unable to cite due to space restrictions. We thank Sitong Liu and Yunzhu Li for assistance with graphic design. We also thank Gabrielle White-Wolf, PhD, from Liwen Bianji, Edanz Editing China, for editing the English text of a draft of this manuscript.

Authors’ contributions
GX and WYX designed the study. GX, WYX, YY and BJ were mainly responsible for data collection and drafted the manuscript. YLM, SDD and ZTZ revised the manuscript. All authors read and approved the final manuscript.

Funding
This study was supported by the National Key Technologies R&D Program (Grant Number: 2015BAI13B09), the National Natural Science Foundation of China (Grant Number: 81972698) and Peking Union Medical College Graduate Student Innovation Fund (Grant Number: 2019-1002-45).

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 13 July 2020   Accepted: 28 September 2020
Published online: 12 October 2020

References
1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.
3. Villanueva A, Minguiez B, Forner A, et al. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med. 2010;61:317–28.
4. Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol. 2014;28(5):753–70.
5. Kudo M. Systemic therapy for hepatocellular carcinoma. 2017 update. Oncology. 2017;93(Suppl 1):3–46.
6. Kataoka M, Wang DZ. Non-coding RNAs including miRNAs and IncRNAs in cardiovascular biology and disease. Cells. 2014;3(3):883–98.
7. Lin MT, Song HJ, Ding XY. Long non-coding RNAs involved in metastasis of gastric cancer. World J Gastroenterol. 2018;24(33):3724–37.
8. Shi B, Zhang X, Chao L, et al. Comprehensive analysis of key genes, microRNAs and long non-coding RNAs in hepatocellular carcinoma. FEBS Open Bio. 2018;8(9):1424–36.
9. Lin X, Chen Y. Identification of potentially functional circRNA-miRNA-miRNA regulatory network in hepatocellular carcinoma by integrated microarray analysis. Med Sci Monit Basic Res. 2018;24:70–80.
10. Wang L, Guo ZY, Zhang R, et al. Pseudogene OCT4-pg4 functions as a natural micro RNA sponge to regulate OCT4 expression by competing for miR-145 in hepatocellular carcinoma. Carcinogenesis. 2013;34(8):1773–81.
11. Salmena L, Poliseno L, Tay Y, et al. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 2011;146(3):353–8.
12. Wang J, Liu X, Wu H, et al. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res. 2010;38(16):5366–83.
13. Ma MZ, Chu BF, Zhang Y, et al. Long non-coding RNA CCAT1 promotes gallbladder cancer development via negative modulation of miRNA-218-5p. Cell Death Dis. 2015;6:e1583.

Abbreviations
HCC: Hepatocellular carcinoma; ceRNA: Competing endogenous RNA; ncRNA: Non-coding RNA; miRNA: MicroRNA; IncRNA: Long non-coding RNA; circRNA: Circular RNA; mRNA: Messenger RNA; MRE: MicroRNA response element; ceRNET: Competing endogenous RNA regulatory network; Ago: Argonaute; EMT: Epithelial-mesenchymal transition; AFP: Alpha-fetoprotein; AUC: Area under the curve.
56. Wang J, Pu J, Zhang Y, et al. DANCR contributed to hepatocellular carci-
noma malignancy via sponing miR-216a-5p and modulating KLF12. J Cell Physiol. 2019;234(6):9408–16.
57. Tsang FH, Au SL, Wei L, et al. Long non-coding RNA HOTTIP is frequently up-regulated in hepatocellular carcinoma and is targeted by tumour suppressive miR-125b. Liver Int. 2015;35(5):1597–606.
58. Yuan JH, Yang F, Wang F, et al. A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell. 2014;25(5):666–81.
59. Wang F, Ying HQ, He BS, et al. Upregulated IncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway. Oncotarget. 2015;6(10):7899–917.
60. Xiao JH, Yan TH, Yu RM, et al. Long non-coding RNA UCA1 regulates the expression of Snail2 by miR-203 to promote hepatocellular carcinoma progression. J Cancer Res Clin Oncol. 2017;143(6):961–90.
61. Li B, Mao R, Liu C, et al. LncRNA FAL1 promotes cell proliferation and migration by acting as a ceRNA of miR-1236 in hepatocellular carcinoma cells. Life Sci. 2018;197:122–9.
62. Yan X, Zhang D, Wu W, et al. Mesenchymal Stem Cells Promote Hepato-
carcinogenesis via IncRNA-MUFI Interaction with ANXA2 and miR-34a. Cancer Res. 2017;77(23):6704–16.
63. Wang H, Huo X, Yang XR, et al. STAT3-mediated upregulation of IncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. Mol Cancer. 2017;16(1):136.
64. Dong J, Teng F, Guo W, et al. IncRNA SNHG8 promotes the tumo-
rigenesis and metastasis by sponging miR-149-5p and predicts tumor recurrence in hepatocellular carcinoma. Cell Physiol Biochem. 2018;51(5):2262–74.
65. Huang Y, Xiang B, Liu Y, et al. LncRNA CDKN2B-AS1 promotes tumor growth and metastasis of human hepatocellular carcinoma by targeting let-7c-3p/NAP1L1 axis. Cancer Lett. 2018;437:56–66.
66. Zhang K, Zhao Z, Yu J, et al. LncRNA FLVCR1-AS1 acts as miR-513c sponge to modulate cancer cell proliferation, migration, and invasion in hepatocellular carcinoma. J Cell Biochem. 2018;119(7):6045–56.
67. Li T, Xie J, Shen C, et al. Amplification of Long Noncoding RNA ZFAS1 Promotes Metastasis in Hepatocellular Carcinoma. Cancer Res. 2015;75(15):3181–91.
68. Zhang XN, Zhou J, Lu XJ. The long non-coding RNA NEAT1 contributes to hepatocellular carcinoma development by sponging miR-485 and enhancing the expression of the STAT3. J Cell Physiol. 2018;233(9):6733–41.
69. He C, Liu Z, Jin L, et al. IncRNA TUG1-Mediated Mirc-142-3p Downregulation Contributes to Metastasis and the Epithelial-to-Mesenchymal Transition of Hepatocellular Carcinoma by Targeting ZEB1. Cell Physiol Biochem. 2018;48(5):1928–41.
70. Lv J, Kong Y, Gao Z, et al. LncRNA TUG1 interacting with miR-1236 promotes metastasis in hepatocellular carcinoma by targeting lncRNA SNHG6-003. Cancer Cell Int. 2019;19:198.
71. Ji D, Hu G, Zhang X, et al. Long non-coding RNA DSCAM-AS1 accelerates the progression of hepatocellular carcinoma via sponging miR-338-3p. Am J Transl Res. 2019;11(7):4290–302.
72. Kong Q, Zhang S, Liang C, et al. LncRNA XIST functions as a molecular sponge of miR-194-5p to regulate MAPK1 expression in hepatocellular carcinoma cell. J Cell Biochem. 2018;119(6):4548–68.
73. Zhang Y, Zhu Z, Huang H, et al. LncRNA XIST regulates the progression of hepatocellular carcinoma via sponging miR-123-5p and targeting PDCD4. Cancer Cell. 2019;19:198.
74. Zhuang LK, Yang YT, Ma X, et al. MicroRNA-29b promotes hepatocellular carcinoma progression by targeting Smad7 and is mediated by long non-coding RNA XIST. Cell Death Dis. 2016;7:e2203.
75. Hu B, Cai H, Zheng R, et al. Long non-coding RNA 657 suppresses hepatocellular carcinoma cell growth by acting as a molecular sponge of miR-106a-5p to regulate PTEN expression. Int J Biochem Cell Biol. 2017;92:34–42.
76. Liu Z, Chen JY, Zhang Y, et al. IncRNA MEG3 inhibits the growth of hepatocellular carcinoma cells by sponging miR-9-5p to upregulate SOX11. Braz J Med Biol Res. 2019;52(10):e8631.
77. Xu F, Zha G, Wu Y, et al. Overexpression IncRNA SNHG16 inhibited HCC proliferation and chemoresistance by functionally sponging hsa-
mir-93. Onco Targets Ther. 2018;11:8855–63.
78. Wang Y, Liu Z, Yao B, et al. Long non-coding RNA CASC2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CASC2/miR-367/FOXW1 axis. Mol Cancer. 2017;16(1):123.
79. Yan S, Tang Z, Chen K, et al. Long noncoding RNA MR151HG inhibits hepatocellular carcinoma proliferation and metastasis by sponging microRNA-575 to modulate ST7L expression. J Exp Clin Cancer Res. 2018;37(1):214.
80. Liu F, Yuan JH, Huang JF, et al. Long noncoding RNA FTX inhibits hepato-
cellular carcinoma proliferation and metastasis by binding miR-125 and miR-374a. Oncogene. 2016;35(41):5422–34.
81. Suzuki H, Zuo Y, Wang J, et al. Characterization of Rnas R-digested cellular RNA source that consists of lariat and circular RNAs from pre-
mRNA splicing. Nucleic Acids Res. 2006;34(8):e63.
82. Suzuki H, Tsukahara T. A view of pre-mRNA splicing from RNase R resist-
ant RNAs. Int J Mol Sci. 2014;15(8):9331–42.
83. Hu ZQ, Zhou SL, Li J, et al. Circular RNA Sequencing Identifies CircASAP1 as a Key Regulator in Hepatocellular Carcinoma Metastasis. Aging. 2019. https://doi.org/10.1002/hep.31068.
84. Su Y, Lv X, Yin W, et al. CircRNA Cdr1as functions as a competitive endogenous RNA to promote hepatocellular carcinoma progression. Aging. 2019;11(19):8182–203.
85. Yu L, Gong X, Sun L, et al. The Circular RNA Cdr1as Act as an Oncogene in Hepatocellular Carcinoma through Targeting miR-7 Expression. PLoS One. 2016;11(7):e0158347.
86. Bai N, Peng E, Xia F, et al. CircABCC2 regulates hepatocellular cancer progression by decoying MiR-665. J Cancer. 2019;10(17):3893–8.
87. Yu J, Yang M, Zhou B, et al. CircRNA-104718 acts as competing endogenous RNA and promotes hepatocellular carcinoma progression through microRNA-218-5p/TNDCS signaling pathway. Clin Sci (Lond). 2019;133(1):1487–503.
88. Zhang X, Xu Y, Qian Z, et al. circRNA_104075 stimulates YAP-dependent tumorigenesis through the regulation of HNF4a and may serve as
Bai N, Peng E, Qiu X, et al. circFBLIM1 act as a ceRNA to promote hepatocellular cancer progression by sponging mir-346. J Exp Clin Cancer Res. 2018;37(1):172.

Huang XY, Huang ZL, Zhang PB, et al. CircRNA-100338 is associated with the miR15/16 pathway and poor prognosis in hepatocellular carcinoma. Front Oncol. 2019;9:392.

Zhu Q, Lu G, Luo Z, et al. CircRNA circ_0067934 promotes tumor growth and metastasis in hepatocellular carcinoma through regulation of miR-1324/FZD5/Wnt/beta-catenin axis. Biomech Biophys Res Commun. 2018;497(2):626–32.

Xie B, Zhao Z, Liu Q, et al. CircRNA has_circ_0078710 acts as the sponge of microRNA-31 involved in hepatocellular carcinoma progression. Gene. 2019;683:253–61.

Wang B, Chen H, Zhang C, et al. Effects of hsa_circRBM23 on hepatocellular carcinoma cell growth and invasion. Cell Cycle. 2019;18(7):2199–206.

Guo J, Duan H, Li Y, et al. A novel circular RNA circ-ZNF652 promotes hepatocellular carcinoma metastasis through inhibiting miR-20a target gene. J Hepatol. 2019;71(2):326–35.

Wei Y, Chen X, Liang C, et al. A noncoding regulatory RNAs network driven by Circ-CDYL acts specifically in the early stages Hepatocellular carcinoma. Hepatology. 2019. https://doi.org/10.1002/hep.30795.

Zhang H, Deng T, Ge S, et al. Exosome circRNA secreted from adipocytes promotes the growth of hepatocellular carcinoma by targeting deubiquitination-related USP7. Oncogene. 2019;38(15):2844–59.

Li S, Gu H, Huang Y, et al. Circular RNA 101368/miR-200a axis modulates the migration of hepatocellular carcinoma through HMG18/RAGE signaling. Cell Cycle. 2018;17(9–10):2349–59.

Liu H, Xue L, Song C, et al. Overexpression of circular RNA circ_001569 indicates poor prognosis in hepatocellular carcinoma and promotes cell growth and metastasis by sponging miR-411-5p and miR-432-5p. Biochem Biophys Res Commun. 2018;503(4):2659–65.

Liu T, Tan J, Gao W, et al. Circular RNA circ_0013754 promotes hepatocellular carcinoma tumorigenesis through miR-486/CDK4 pathway. J Cell Physiol. 2018;234(1):500–08.

Qiu L, Huang Y, Li Z, et al. Circular RNA profiling identifies circADAMTS13 as a miR-484 sponge which suppresses cell proliferation in hepatocellular carcinoma. Mol Oncol. 2019;13(2):441–55.

Yang X, Song H, Zi Z, et al. Circ_0005075 promotes hepatocellular carcinoma progression by sponging microRNA-421 inhibiting hepatocellular carcinoma growth. J Exp Clin Cancer Res. 2019;38(1):98.

Zhang PF, Wei CY, Huang XY, et al. Circular RNA cTRIM33-12 acts as the sponge of microRNA-191 to suppress hepatocellular carcinoma progression. Mol Cancer. 2019;18(1):105.

He S, Guo Z, Kang Q, et al. Circular RNA hsa_circ_0000517 modulates the epithelial-mesenchymal transition by sponging miR-370-5p. Aging. Cell Death Dis. 2018;9(11):124–27.

Xu L, Peng X, Hao X, et al. CircSETD3 (Hsa_circ_0000567) acts as a sponge for microRNA-421 inhibiting hepatocellular carcinoma growth. J Exp Clin Cancer Res. 2019;38(1):98.
155. Xie F, Feng S, Sun L, et al. The first-line treatment for unresectable hepatocellular carcinoma patients: lenvatinib versus sorafenib, or beyond? Hepatobiliary Surg Nutr. 2018;7(3):221–24.

156. Abd El Gwad A, Matboli M, El-Tawdi A, et al. Role of exosomal competing endogenous RNA in patients with hepatocellular carcinoma. J Cell Biochem. 2018;119(10):8600–10.

157. Wang X, Fang L. Advances in circular RNAs and their roles in breast Cancer. J Exp Clin Cancer Res. 2018;37(1):206.

158. Xu YH, Deng JL, Wang G, et al. Long non-coding RNAs in prostate cancer: Functional roles and clinical implications. Cancer Lett. 2019;464:37–55.

159. Ming XL, Feng YL, He DD, et al. Role of BCYRN1 in hepatocellular carcinoma pathogenesis by IncRNA-miRNA-mRNA network analysis and its diagnostic and prognostic value. Epigenomics. 2019;11(10):1209–31.

160. Ding S, Jin Y, Hao Q, et al. LncRNA BCYRN1/miR-490-3p/POU3F2, served as a ceRNA network, is connected with worse survival rate of hepatocellular carcinoma patients and promotes tumor cell growth and metastasis. Cancer Cell Int. 2020;20:6.

161. Bai Y, Long J, Liu Z, et al. Comprehensive analysis of a ceRNA network reveals potential prognostic cytoplasmic IncRNAs involved in HCC progression. J Cell Physiol. 2019;234(10):18857–48.

162. Long J, Bai Y, Yang X, et al. Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for hepatocellular carcinoma. Cancer Cell Int. 2019;19:90.

163. Liao X, Wang X, Huang K, et al. Integrated analysis of competing endogenous RNA network revealing potential prognostic biomarkers of hepatocellular carcinoma. J Cancer. 2019;10(14):3267–83.

164. Seo H, Kim W, Lee J, et al. Network-based approaches for anticancer therapy (Review). Int J Oncol. 2013;43(6):1737–44.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.